Breadcrumb

[A19-54] Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12

Overview

Overview

Commission: Commission awarded on 2019-06-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commissions A19-11 and A19-12  [PDF, 317 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A19-12] Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A19-11] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-08-15 Addendum to Commissions A19-11 and A19-12 317 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2019-08-15 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close